Compare BridgeBio Pharma Inc (BBIO) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ON Holding AG — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while ON Holding AG trades at $31.2 (market cap $12.93B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals.
| BBIO | ONON | |
|---|---|---|
Market Cap | $16.61B | $12.93B |
Sector | Health | Technology |
52-Week High | $90.17 | $50.63 |
52-Week Low | $47.29 | $30.91 |
Enterprise Value | $18.16B | $12.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ONON trades at $37.55, up 0.56% with bullish technical signals supported by moving averages. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $0.47 vs. $0.34 expected, maintaining a streak of earnings surprises. Revenue growth to $3.01B in 2025 and expanding net margins to 8.02% reflect operational strength amid positive analyst sentiment.
The outlook remains positive with 77% analyst buy ratings and $52.57 consensus price target suggesting 40% upside potential. Key risks include premium valuation metrics (P/E 41.8, P/S 6.5) and tariff exposure, but strong DTC growth and margin expansion support the bullish case for growth investors seeking athletic footwear exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
